查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493227

ADHD（注意力不足过动症）市场规模、份额、趋势分析报告：按药物类型、人口统计、分销管道、地区、细分市场预测，2024-2030 年

Attention Deficit Hyperactivity Disorder Market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Demographics (Children, Adults), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

ADHD（注意力不足过动症）市场成长与趋势：

Grand View Research的最新报告显示，到2030年，全球ADHD（注意力不足过动症）市场规模预计将达到186亿美元。

预计 2024 年至 2030 年该市场将以 3.7% 的复合年增长率扩张。强大的产品平臺的存在以及多动症治疗的后续核准预计将推动市场成长。后期管道包括Neurocentria, Inc.开发的NRCT-101、Supernus Pharmaceuticals, Inc.开发的SPN-812和大冢美国製药公司开发的EB-1020。

政府机构正在采取的有关多动症早期诊断和治疗的几项倡议可能会支持市场成长。 2021 年 1 月，澳洲政府将 Vyvanse 纳入治疗成人 ADHD 的药物福利计划 (PBS)。透过此应用程序，Vyvanse 现在可以以补贴价格向患者提供服务，超过 20,000 名患者以较低的成本接受类似的治疗。如果没有 PBS 的津贴，患者每年将不得不支付超过 1,200 美元的治疗费用。纳入 PBS 后，治疗费用为每次治疗 41.30 美元。预计此类倡议也将推动市场成长。

患者、医生和其他医疗保健提供者对 ADHD 的认识不断提高，可能会增加对诊断和治疗的需求，从而推动 ADHD（注意力不足过动症）市场的成长。 ADHD（注意力不足过动症）辅导组织 (ACO) 将 10 月定为 ADHD 意识月，旨在提高人们的认识，为研究和开发筹集资金，并对人们进行有关该疾病的教育。这项措施可以促进早期诊断并提高产品普及。

然而，患有多动症的儿童与其他精神疾病合併症的风险很高，这往往使诊断和治疗变得复杂。根据灵北基金会 2021 年发布的一项研究，患有註意力不足过动症且患有其他精神疾病的人更有可能避免服药。过动症儿童常见的合併症包括忧郁症、焦虑症、躁郁症、学习障碍、早期语言和沟通障碍以及对立障碍。

此外，缺乏治疗过动症的兴奋剂药物迫使患者支付昂贵的品牌药物，为行为疗法等替代疗法腾出空间，并对过动症药物治疗的需求产生负面影响。美国缉毒局 (DEA) 等监管机构实施了严格的法规，限制过动症药物的生产，以避免误用和滥用。随着需求的增加，可能会出现药物短缺，导致治疗成本更高并限制市场成长。因此，药品短缺可能会阻碍市场成长。

ADHD（注意力不足过动症）市场报告亮点

  • 按药物类型划分，由于对这些药物和症状管理的高需求、政府对使用兴奋剂药物的支持以及针对ADHD（注意力不足过动症）的持续临床试验，兴奋剂细分市场将在2023 年成为最大的市场。
  • 从人口统计来看，由于目标人口庞大且开拓ADHD（注意力不足过动症）的风险较高，2023 年 ADHD（注意力不足过动症）市场将由成人市场主导。据 ADD Health and Wellness Centers, Inc. 称，这种疾病影响着大约 4% 到 5% 的成年人口。
  • 预计 2023 年 ADHD（注意力不足过动症）市场将在预测期内出现最快的成长，主要由市场细分领域主导。这是因为 ADHD（注意力不足过动症）药物在零售药局随处可见，患者很容易取得。
  • 由于医疗保健专业人员对可用于治疗的药物的认识较高以及疾病盛行率上升等因素，北美在 2023 年将主导全球市场。据加拿大 ADHD 意识中心 (CADDAC) 称，这种疾病影响加拿大超过 150 万人。
  • 亚太地区预计将成为预测期内成长最快的地区，从而增加该地区过动症的盛行率和治疗需求。例如，ADHD 是最常见的神经发育障碍之一，在澳大利亚，大约 8.2% 的儿童和 11% 的男孩被诊断出患有 ADHD。

目录

第一章调查方法和范围

第 2 章 第 2 章执行摘要

  • 市场展望
  • 分部展望
    • 药品类型展望
    • 人口前景
    • 分销通路展望
    • 区域展望
  • 竞争考察

第 3 章 ADHD（注意力不足过动症）市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • ADHD（注意力不足过动症）市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 ADHD（注意力不足过动症）市场：药物类型的估计和趋势分析

  • 2023 年和 2030 年按药物类型分類的市场占有率份额
  • 细分仪表板
  • 按药物类型分類的全球过动症（注意力不足过动症）市场展望
  • 2018-2030年市场规模、预测及趋势分析
  • 精神兴奋剂
  • 非精神兴奋剂

第五章 ADHD（注意力不足过动症）市场：人口统计估计与趋势分析

  • 2023 年和 2030 年按人口统计的市场占有率
  • 细分仪表板
  • 全球 ADHD（注意力不足过动症）市场展望（按人口统计）
  • 2018-2030年市场规模、预测及趋势分析
  • 孩子
  • 成人

第六章 ADHD（注意力不足过动症）市场：通路估计与趋势分析

  • 2023 年及 2030 年分销通路市场占有率
  • 细分仪表板
  • 按分销管道划分：全球 ADHD（注意力不足过动症）市场展望
  • 2018-2030年市场规模、预测及趋势分析
  • 医院药房
  • 零售药房

第七章 ADHD（注意力不足过动症）市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第8章 8 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Pfizer, Inc.
    • Johnson &Johnson Services, Inc.
    • Lupin
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Mallinckrodt plc.
    • Purdue Pharma Lp
    • Supernus Pharmaceuticals, Inc.
    • NEOS Therapeutics, Inc.
    • HS Hospital Service SpA
Product Code: GVR-2-68038-795-7

Attention Deficit Hyperactivity Disorder Market Growth & Trends:

The global attention deficit hyperactivity disorder market size is expected to reach USD 18.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.7% from 2024 to 2030. The presence of a strong product pipeline for the treatment of ADHD and their subsequent approval is expected to boost the market growth. Some late-stage pipeline products are NRCT-101 developed by Neurocentria, Inc., SPN-812 by Supernus Pharmaceuticals, Inc., and EB-1020 by Otsuka America Pharmaceutical, Inc.

Several initiatives undertaken by government bodies regarding early diagnosis and treatment of ADHD are likely to support the market growth. In January 2021, the Australian Government included Vyvanse under its Pharmaceutical Benefits Scheme (PBS) for the treatment of adult patients with ADHD. This inclusion makes the availability of Vyvanse at a subsidized rate to patients and more than 20,000 patients received a comparable treatment for the disease at low cost and benefits. Without PBS subsidy, the patients had to pay more than USD 1,200 per person annually for their treatment. After the inclusion in PBS, they will receive the treatment at USD 41.30 per script. Such initiatives are also expected to drive market growth.

Increasing awareness about ADHD among patients, physicians, and other healthcare providers may increase the demand for diagnosis and treatment which in turn propel the growth of the attention deficit hyperactivity disorder market. The Attention Deficit Hyperactivity Disorder Coaches Organization (ACO) celebrates October as the ADHD awareness month intending to raise awareness, generate funding for R&D, and educate people about disorders. This initiative may boost early diagnosis, thereby, increasing product penetration.

However, the risk of comorbidity with other psychiatric disorders is high among children with ADHD, often making diagnosis and treatment of the disorder complex. A research study published by the Lundbeck Foundation in 2021 showed that ADHD patients with other psychiatric comorbid conditions were more likely to avoid taking medicines. Some of the comorbid conditions that typically occur in ADHD pediatric patients are depression, anxiety, bipolar disorder, learning disorder, early speech/communication problems, and oppositional defiant disorder.

Furthermore, the shortage of stimulants to treat ADHD has forced patients to pay for expensive branded medication and create scope for substitute therapies, such as behavioral therapy, which will negatively impact the demand for ADHD pharmacological therapies. Strict regulations are implemented by regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), which limit the production of ADHD drugs to avoid misuse or abuse. Amid an increase in demand, this can create a shortage of medical products, consequently increasing the cost of treatments and restraining market growth. Thus, the shortage of medicines may impede the market growth.

Attention Deficit Hyperactivity Disorder Market Report Highlights:

  • By drug type, the stimulants segment accounted for the largest share of the market in 2023 due to the high demand for these medicines and the management of symptoms, government support for the use of stimulants drugs, and continuing clinical trials regarding attention deficit hyperactive disorder
  • Based on demographics, the adults segment dominated the attention-deficit hyperactivity disorder market in 2023 owing to the large target population base and high risk of developing the attention-deficit hyperactive disorder. According to ADD Health and Wellness Centers, Inc. the disorder affects approximately 4-5% of the adult population
  • Retail pharmacy segment dominated the attention-deficit hyperactivity disorder market in 2023 and is anticipated to witness the fastest growth over the forecast period. This can be attributed to the wide availability of attention deficit hyperactivity disorder drugs at retail pharmacies and their ease of accessibility to patients
  • North America dominated the global market in 2023 owing to factors such as high awareness among healthcare professionals about drugs available for treatment and the rise in disease prevalence. According to the Center for ADHD Awareness Canada (CADDAC), more than 1.5 million people are affected by the disease in Canad
  • Asia Pacific is expected to be the fastest-growing region during the forecast period to increasing ADHD prevalence and treatment demand in the region. For instance, ADHD is one of the most common neurodevelopment diseases with approximately 8.2% of children and 11% of boys diagnosed in Australia

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug type
    • 1.2.2. Demographics
    • 1.2.3. Distribution channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Chapter 2 Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug type outlook
    • 2.2.2. Demographics outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Attention Deficit Hyperactivity Disorder Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of ADHD
      • 3.2.1.2. Increasing awareness about ADHD Among Physicians And Patients
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Shortage of ADHD drugs
      • 3.2.2.2. Low availability of non-stimulant ADHD drugs
      • 3.2.2.3. Comorbidities leading to underdiagnosis in children
  • 3.3. Attention Deficit Hyperactivity Disorder Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Attention Deficit Hyperactivity Disorder Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Attention Deficit Hyperactivity Disorder Market by Drug Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Stimulants
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Amphetamine
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Methylphenidate
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lisdexamfetamine
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Dexmethylphenidate
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non stimulants
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Atomoxetine
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Guanfacine
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Clonidine
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. Others
      • 4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Attention Deficit Hyperactivity Disorder Market: Demographics Estimates & Trend Analysis

  • 5.1. Demographics Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Attention Deficit Hyperactivity Disorder Market by Demographics Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Children
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Adults
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Distribution Channel Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Attention Deficit Hyperactivity Disorder Market by Distribution Channel Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Hospital pharmacy
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Retail pharmacy
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Attention Deficit Hyperactivity Disorder Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Chapter 8 Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Pfizer, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lupin
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Novartis AG
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Takeda Pharmaceutical Company Limited
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Mallinckrodt plc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Purdue Pharma L.p
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Supernus Pharmaceuticals, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. NEOS Therapeutics, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. H.S. Hospital Service S.p.A.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America attention deficit hyperactivity disorder market, 2018 - 2030 (USD Million)
  • Table 3 North America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 4 North America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 5 North America attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 U.S. attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 8 U.S. attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Canada attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 11 Canada attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Europe attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 14 Europe attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 15 Europe attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Germany attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Germany attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 18 Germany attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 UK attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 UK attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 21 UK attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 France attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 24 France attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Italy attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 Italy attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 27 Italy attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Spain attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Spain attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 30 Spain attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Denmark attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 Denmark attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 33 Denmark attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Sweden attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 Sweden attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 36 Sweden attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Norway attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Norway attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 39 Norway attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Japan attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 45 Japan attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 46 Japan attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 48 China attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 49 China attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 India attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 India attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 52 India attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 South Korea attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 55 South Korea attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Australia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 57 Australia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 58 Australia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 Thailand attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 61 Thailand attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 64 Latin America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 65 Latin America attention deficit hyperactivity disorder n market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Brazil attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 Brazil attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 68 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Mexico attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 73 Mexico attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 74 Mexico attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Argentina attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 76 Argentina attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 77 Argentina attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 MEA Attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
  • Table 79 MEA attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 80 MEA attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 81 MEA attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Africa attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 South Africa attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 84 South Africa attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 UAE attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 89 UAE attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 90 UAE attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Kuwait attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
  • Table 92 Kuwait attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
  • Table 93 Kuwait attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Attention deficit hyperactivity disorder market: Market outlook
  • Fig. 9 Attention deficit hyperactivity disorder market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Attention deficit hyperactivity disorder market driver impact
  • Fig. 14 Attention deficit hyperactivity disorder market restraint impact
  • Fig. 15 Attention deficit hyperactivity disorder market: Drug type movement analysis
  • Fig. 16 Attention deficit hyperactivity disorder market: Drug type outlook and key takeaways
  • Fig. 17 Stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Amphetamine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Methylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Lisdexamfetamine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Dexmethylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Non-stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Atomoxetine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Guanfacine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Clonidine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Attention deficit hyperactivity disorder Market: Demographics movement Analysis
  • Fig. 28 Attention deficit hyperactivity disorder market: Demographics outlook and key takeaways
  • Fig. 29 Children market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Attention deficit hyperactivity disorder market: Distribution channel movement analysis
  • Fig. 32 Attention deficit hyperactivity disorder market: Distribution channel outlook and key takeaways
  • Fig. 33 Hospital pharmacy; market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Global attention deficit hyperactivity disorder market: Regional movement analysis
  • Fig. 36 Global attention deficit hyperactivity disorder market: Regional outlook and key takeaways
  • Fig. 37 North America
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S.
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Japan
  • Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 China
  • Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 India
  • Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea
  • Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Australia
  • Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Thailand
  • Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America
  • Fig. 76 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil
  • Fig. 78 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico
  • Fig. 80 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa
  • Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Africa
  • Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Saudi Arabia
  • Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 UAE
  • Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Kuwait
  • Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)